| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
UNC Lineberger Comprehensive Cancer Center [E-M. W., A. M., J. S., S. C. K.], and Department of Medicine [S. C. K.], University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, and Department of Virology, Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709 [M. G. D., C. L. T.]
The consistent presence of EBV genomes in certain tumor types (in particular, AIDS-related central nervous system lymphomas and nasopharyngeal carcinomas) may allow novel, EBV-based targeting strategies. Tumors contain the latent (transforming) form of EBV infection. However, expression of either of the EBV immediate-early proteins, BZLF1 and BRLF1, is sufficient to induce lytic EBV infection, resulting in death of the host cell. We have constructed replication-deficient adenovirus vectors expressing the BZLF1 or BRLF1 immediate-early genes and examined their utility for killing latently infected lymphoma cells in vitro and in vivo. We show that both the BZLF1 and BRLF1 vectors efficiently induce lytic EBV infection in Jijoye cells (an EBV-positive Burkitt lymphoma cell line). Furthermore, lytic EBV infection converts the antiviral drug, ganciclovir (GCV), into a toxic (phosphorylated) form, which inhibits cellular as well as viral DNA polymerase. When Jijoye cells are infected with the BZLF1 or BRLF1 adenovirus vectors in the presence of GCV, viral reactivation is induced, but virus replication is inhibited (thus preventing the release of infectious EBV particles); yet cells are still efficiently killed. Finally, we demonstrate that the BZLF1 and BRLF1 adenovirus vectors induce lytic EBV infection when they are directly inoculated into Jijoye cell tumors grown in severe combined immunodeficiency mice. These results suggest that induction of lytic EBV infection in tumors, in combination with GCV, may be an effective strategy for treating EBV-associated malignancies.
This article has been cited by other articles:
|
|
 |
|
  M. C. Chia, A. Leung, T. Krushel, N. M. Alajez, K. W. Lo, P. Busson, H. J. Klamut, C. Bastianutto, and F.-F. Liu Nuclear Factor-Y and Epstein Barr Virus in Nasopharyngeal Cancer Clin. Cancer Res., February 15, 2008; 14(4): 984 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-h. Feng, R. J. Kraus, S. J. Dickerson, H. J. Lim, R. J. Jones, X. Yu, J. E. Mertz, and S. C. Kenney ZEB1 and c-Jun Levels Contribute to the Establishment of Highly Lytic Epstein-Barr Virus Infection in Gastric AGS Cells J. Virol., September 15, 2007; 81(18): 10113 - 10122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-T. Wang, P.-W. Yang, C.-P. Lee, C.-H. Han, C.-H. Tsai, and M.-R. Chen Detection of Epstein-Barr virus BGLF4 protein kinase in virus replication compartments and virus particles J. Gen. Virol., December 1, 2005; 86(12): 3215 - 3225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Daibata, K. Bandobashi, M. Kuroda, S. Imai, I. Miyoshi, and H. Taguchi Induction of Lytic Epstein-Barr Virus (EBV) Infection by Synergistic Action of Rituximab and Dexamethasone Renders EBV-Positive Lymphoma Cells More Susceptible to Ganciclovir Cytotoxicity In Vitro and In Vivo J. Virol., May 1, 2005; 79(9): 5875 - 5879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Holley-Guthrie, W. T. Seaman, P. Bhende, J. L. Merchant, and S. C. Kenney The Epstein-Barr Virus Protein BMRF1 Activates Gastrin Transcription J. Virol., January 15, 2005; 79(2): 745 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, N. P. Mahajan, J. Webster-Cyriaque, P. Bhende, G. K. Hong, H. S. Earp, and S. Kenney The C-Mer Gene Is Induced by Epstein-Barr Virus Immediate-Early Protein BRLF1 J. Virol., November 1, 2004; 78(21): 11778 - 11785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Makhov, D. Subramanian, E. Holley-Guthrie, S. C. Kenney, and J. D. Griffith The Epstein-Barr Virus Polymerase Accessory Factor BMRF1 Adopts a Ring-shaped Structure as Visualized by Electron Microscopy J. Biol. Chem., September 24, 2004; 279(39): 40358 - 40361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Hong, H.-J. Delecluse, H. Gruffat, T. E. Morrison, W.-H. Feng, A. Sergeant, and S. C. Kenney The BRRF1 Early Gene of Epstein-Barr Virus Encodes a Transcription Factor That Enhances Induction of Lytic Infection by BRLF1 J. Virol., May 15, 2004; 78(10): 4983 - 4992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, J. Webster-Cyriaque, C. C. Tomlinson, M. Yohe, and S. Kenney Fatty Acid Synthase Expression Is Induced by the Epstein-Barr Virus Immediate-Early Protein BRLF1 and Is Required for Lytic Viral Gene Expression J. Virol., April 15, 2004; 78(8): 4197 - 4206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-h. Feng, G. Hong, H.-J. Delecluse, and S. C. Kenney Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas J. Virol., February 15, 2004; 78(4): 1893 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Morrison, A. Mauser, A. Klingelhutz, and S. C. Kenney Epstein-Barr Virus Immediate-Early Protein BZLF1 Inhibits Tumor Necrosis Factor Alpha-Induced Signaling and Apoptosis by Downregulating Tumor Necrosis Factor Receptor 1 J. Virol., January 1, 2004; 78(1): 544 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mauser, S.'i. Saito, E. Appella, C. W. Anderson, W. T. Seaman, and S. Kenney The Epstein-Barr Virus Immediate-Early Protein BZLF1 Regulates p53 Function through Multiple Mechanisms J. Virol., November 13, 2002; 76(24): 12503 - 12512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mauser, E. Holley-Guthrie, A. Zanation, W. Yarborough, W. Kaufmann, A. Klingelhutz, W. T. Seaman, and S. Kenney The Epstein-Barr Virus Immediate-Early Protein BZLF1 Induces Expression of E2F-1 and Other Proteins Involved in Cell Cycle Progression in Primary Keratinocytes and Gastric Carcinoma Cells J. Virol., November 13, 2002; 76(24): 12543 - 12552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-h. Feng, E. Westphal, A. Mauser, N. Raab-Traub, M. L. Gulley, P. Busson, and S. C. Kenney Use of Adenovirus Vectors Expressing Epstein-Barr Virus (EBV) Immediate-Early Protein BZLF1 or BRLF1 To Treat EBV-Positive Tumors J. Virol., October 2, 2002; 76(21): 10951 - 10959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mauser, E. Holley-Guthrie, D. Simpson, W. Kaufmann, and S. Kenney The Epstein-Barr Virus Immediate-Early Protein BZLF1 Induces both a G2 and a Mitotic Block J. Virol., August 28, 2002; 76(19): 10030 - 10037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-h. Feng, B. Israel, N. Raab-Traub, P. Busson, and S. C. Kenney Chemotherapy Induces Lytic EBV Replication and Confers Ganciclovir Susceptibility to EBV-positive Epithelial Cell Tumors Cancer Res., March 1, 2002; 62(6): 1920 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Darr, A. Mauser, and S. Kenney Epstein-Barr Virus Immediate-Early Protein BRLF1 Induces the Lytic Form of Viral Replication through a Mechanism Involving Phosphatidylinositol-3 Kinase Activation J. Virol., July 1, 2001; 75(13): 6135 - 6142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Swenson, E. Holley-Guthrie, and S. C. Kenney Epstein-Barr Virus Immediate-Early Protein BRLF1 Interacts with CBP, Promoting Enhanced BRLF1 Transactivation J. Virol., July 1, 2001; 75(13): 6228 - 6234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Israel, R. J. Pickles, D. M. Segal, R. D. Gerard, and S. C. Kenney Enhancement of Adenovirus Vector Entry into CD70-Positive B-Cell Lines by Using a Bispecific CD70-Adenovirus Fiber Antibody J. Virol., June 1, 2001; 75(11): 5215 - 5221. [Abstract] [Full Text]
|
|
|
|
|
|
A. L. Adamson and S. Kenney Epstein-Barr Virus Immediate-Early Protein BZLF1 Is SUMO-1 Modified and Disrupts Promyelocytic Leukemia Bodies J. Virol., March 1, 2001; 75(5): 2388 - 2399. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. Westphal, W. Blackstock, W. Feng, B. Israel, and S. C. Kenney Activation of Lytic Epstein-Barr Virus (EBV) Infection by Radiation and Sodium Butyrate in Vitro and in Vivo: A Potential Method for Treating EBV-positive Malignancies Cancer Res., October 1, 2000; 60(20): 5781 - 5788. [Abstract] [Full Text]
|
|
|
|
|
|
M. Schuler, E. Bossy-Wetzel, J. C. Goldstein, P. Fitzgerald, and D. R. Green p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release J. Biol. Chem., March 15, 2000; 275(10): 7337 - 7342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Adamson, D. Darr, E. Holley-Guthrie, R. A. Johnson, A. Mauser, J. Swenson, and S. Kenney Epstein-Barr Virus Immediate-Early Proteins BZLF1 and BRLF1 Activate the ATF2 Transcription Factor by Increasing the Levels of Phosphorylated p38 and c-Jun N-Terminal Kinases J. Virol., February 1, 2000; 74(3): 1224 - 1233. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Von Seggern, S. Huang, S. K. Fleck, S. C. Stevenson, and G. R. Nemerow Adenovirus Vector Pseudotyping in Fiber-Expressing Cell Lines: Improved Transduction of Epstein-Barr Virus-Transformed B Cells J. Virol., January 1, 2000; 74(1): 354 - 362. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
